ClinicalTrials.gg
Active, not recruitingNCT06651632WATER IV PCaUpdated May 4, 2026

WATER IV Prostate Cancer

An interventional study of Aquablation Therapy and Radical Prostatectomy in Localized Prostate Cancer, sponsored by PROCEPT BioRobotics. Active, not recruiting at 37 sites in 7 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by PROCEPT BioRobotics · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
404th of 3,024
280 · median 48
Started
2025
with 160 others
No phase
764 of 3,597
157 open now
Primary completion
2027-07
later than 439 of 968 live
Registered
3,280th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 404th largest by planned enrollment of the 3,024 interventional ones that give a count, is one of 161 that started in 2025, is one of 764 with no phase, reaches primary completion later than 439 of the 968 other live ones, and was the 3,280th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, prospective, randomized clinical trial that aims to assess the safety and efficacy of Aquablation Therapy in men with low-risk to intermediate to high-risk localized prostate cancer who are candidates for, or have opted for, prostatectomy. Participants will be randomized to either Aquablation Therapy or radical prostatectomy and followed up to 10 years.

03

Conditions studied

  • Localized Prostate Cancer

Browse trials for

Keywords

  • Aquablation therapy
  • Aquablation
  • Prostate cancer
  • AQUABEAM
  • radical prostatectomy
  • HYDROS
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Biological male with age ≥ 45 years at the time of consent
  2. positive Grade Group 1-3 prostate cancer
  3. Are candidates for prostatectomy or, in the case of GG1 disease, have already selected a radical therapy as their treatment.
  4. Clinical Stage ≤ T2c
  5. PSA ≤ 20 ng/ml
  6. Prostate volume ≥25 ml

Exclusion criteria

Exclusion Criteria:

  1. Any prior or current local or systemic treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation, hormone therapy or chemotherapy.
  2. Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 3 months of study treatment.
  3. Evidence of lymph node, bone , extracapsular extension or seminal vesicle invasion.
  4. Patient is unwilling to accept a blood transfusion if required.
  5. Any condition or history of illness or surgery that may pose an additional risk to patients undergoing the Aquablation or radical prostatectomy procedure such as:

5a. Medical conditions that preclude the use of anesthesia; 5b. Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of rectal injury (i.e. fistula formation); 5c. Patient is unable to stop anticoagulants or antiplatelet agents prior to study treatment per standard of care; 5d. Any other condition or history of infection, illness or surgery that in the opinion of the investigator might affect the outcome of the study procedure, study conduct, and study results; or pose additional risks to the patient (e.g., other cancer, active urethral stricture disease).

6. Patients who are unable to provide due to cognitive impairment, legal status (such as incarceration), or other factors limiting autonomy or unwilling or unable to follow study instructions including randomization and complete all required study visits through 10 years. This includes individuals with severe cognitive disabilities, those under legal guardianship, or those currently incarcerated.

7. Patient currently participating in other studies unless approved by Sponsor in writing.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Aquablation Therapy

    The Aquablation Therapy arm will receive Aquablation with either the AQUABEAM Robotic System or HYDROS Robotic System

    Device: Aquablation Therapy

  • Active comparator
    Radical Prostatectomy

    The radical prostatectomy arm will receive the standard of care radical prostatectomy procedure.

    Procedure: Radical Prostatectomy

Interventions

  • DeviceAquablation Therapy

    The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy.

  • ProcedureRadical Prostatectomy

    Radical prostatectomy is a surgery that is performed through an incision in the lower abdomen or perineum, or with a laparoscope or robotic system to remove the entire prostate gland.

06

What researchers measure

Primary outcomes

  1. Rate of pad use for urinary incontinence

    Time frame: 6 Months

  2. Rate of erectile dysfunction

    Time frame: 6 Months

Secondary outcomes

  1. Rate of pad use for urinary incontinence

    Time frame: 3 Months

  2. Rate of erectile dysfunction

    Time frame: 3 Months

  3. Stable or improved Grade Group at 1 year compared to baseline (Aquablation arm only)

    Time frame: 1 Year

07

Study locations

37 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jul 2027, 29 months after the start.

Of 58 industry-sponsored interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 29 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2024
First posted
Oct 22, 2024
StartActual
Feb 3, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jan 2037
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06651632
Lead sponsor
PROCEPT BioRobotics
Responsible party
Sponsor
First posted
Oct 22, 2024
Start date
Feb 3, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jan 2037 (estimated)
Last update
May 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion